Navigation Links
Access Pharmaceuticals to Present at Jessup & Lamont 2009 Growth Stock Conference
Date:7/22/2009

DALLAS, July 22 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP) announced today that Jeffrey B. Davis, President & CEO, will present at the Jessup & Lamont 2009 Growth Stock Conference organized by the LifeTech Capital Group on Thursday, July 30, 2009 at 10:45 am EDT. The presentation will occur live and will be held at the Waldorf Astoria Boca Beach Club in Boca Raton, Florida.

"We are pleased to have the opportunity to present Access Pharmaceuticals to the large group of institutional and retail investors that attend Jessup's annual growth stock conference," stated Jeffrey B. Davis, Access' President & CEO. "The conference provides a forum for Access to highlight in many product programs, and specifically the very significant and positive initial results and feedback from the commercial launch of MuGard, our FDA approved treatment for oral mucositis. Initial clinical feedback and experience exceeds our expectations."

About Access: Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase 2 clinical testing of patients with ovarian cancer, and MuGard(TM) for the management of patients with mucositis. The company also has other advanced drug delivery technologies including Cobalamin(TM)-mediated targeted delivery and oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism; Angiolix(R), a humanized monoclonal antibody which acts as an anti-angiogenesis factor and is targeted to breast cancer; and Thiarabine, a new generation nucleoside analog which has demonstrated both pre-clinical and clinical activity in certain cancers. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: clinical trial plans and timelines and clinical results for ProLindac and product candidates acquired in the MacroChem transaction, our ability to execute licensing agreements in the future, Access' plans to continue and initiate clinical trials, the value of its products in the market (including MuGard and the size of the overall market for mucositis products), its ability to achieve clinical and commercial success and its ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited Access' need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access' Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.


'/>"/>
SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Carefx Implements Fusionfx at Fletcher Allen Health Care to Improve Anywhere/Anytime Access to Crucial Patient Information
2. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
3. PTS, Inc. Subsidiary Disability Access Corporation Announces $535,000 in New Contracts and Inspection Orders for July 2009
4. Over 25,000 Pharmacists and Technicians Access PTCB Funded Web-Based Continuing Education Programs
5. National Hospice and Palliative Care Organizations Caring Connections and Google Health Offer New Way to Access Advance Directives Online
6. Access MediQuip Names Tim Hargarten Chief Executive Officer
7. Critical Access Hospital Consolidator Seeks Cost-Management Solutions with Broadlane
8. Better Business Bureau Selects Language Line Services for New Language Access Program
9. Cancer Roadmaps Chooses Tableau Software for Consumer Access to Online, Interactive Dashboards for Cancer Patients
10. TrinityCare Senior Living, Inc. Information to be Available Through Standard & Poors Market Access Program
11. Pennsylvania Governor Rendell Ceremonially Signs Four Health Care Bills That Will Reduce Costs, Improve Access and Quality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... American Family Care (AFC) has opened a ... health care for residents in the area. The Bedford clinic will be the nineteenth ... four years by Dave Adams and Dr. Kristina Orio. Adams and Orio also independently ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... natural supplement for relieving premenstrual syndrome, or PMS . , Most women ... These symptoms can include cramps, constipation, irritability, headaches, fatigue, and other discomfort. ...
(Date:1/24/2017)... ... ... Have Dreamed: A Novel of Miracles”: a beautiful and poignant glimpse into the unexpected ... her life. “Who Would Have Dreamed: A Novel of Miracles” is the creation of published ... , Sharon shares that she started her spiritual journey later in life, but mentions, ...
(Date:1/24/2017)... ... ... Octagon of Spiritual Balances”: a guide for the Christian seeking a path to ... Bernard J. Weathers, pastor of Word of Faith Ministries, in Colonia, New Jersey. ... degree in theology. , ““The Octagon of Spiritual Balances” exposes the deceptive will of ...
(Date:1/24/2017)... ... January 23, 2017 , ... ... house-caliber protein and espresso drink, announced its CLICK® Coffee Protein Drink is now ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... January 24, 2017 www.Financialbuzz.com ... industries in the United States as ... 2016. In addition, Proposition 64, the California Cannabis Legalization Initiative, ... against on November 8, 2016. This outcome means that individuals ... and to grow a certain amount of cannabis for personal ...
(Date:1/24/2017)... , Jan. 24, 2017   QR Pharma ... company developing novel therapies for the treatment of ... the appointment of four world-class key opinion leaders ... appointments join QR Pharma,s previous roster of impressive ... direction to support the development of the breakthrough ...
(Date:1/24/2017)... 2017 Mezzion has filed a suit for ... alleging that Dr. Reddy,s committed fraud relating to Dr. ... Administration (FDA) cGMP practices, and misrepresenting its compliance to ... to Mezzion that it was compliant with FDA regulations, ... suit also states that Dr. Reddy,s misconduct was the ...
Breaking Medicine Technology: